Lung cancers unrelated to smoking: characterized by single oncogene addiction?
- 8 June 2011
- journal article
- review article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 16 (4) , 294-305
Abstract
Lung cancer is a major cause of cancer-related mortality worldwide. Currently, adenocarcinoma is its most common histological subtype in many countries. In contrast with small cell lung cancer or squamous cell carcinoma, lung adenocarcinoma often arises in never-smokers, especially in East Asian countries, as well as in smokers. Adenocarcinoma in never-smokers is associated with a lower incidence of genetic alterations (i.e., somatic mutations, loss of heterozygosity, and methylation) than in smokers. In addition, most adenocarcinomas in never-smokers harbor one of the proto-oncogene aberrations that occur in a mutually exclusive manner (EGFR mutation, KRAS mutation, HER2 mutations, or ALK translocation). It is of note that the proliferation and survival of lung cancer cells that harbor one of these oncogenic aberrations depend on the signaling from each aberrantly activated oncoprotein (oncogene addiction). Therefore, most adenocarcinomas in never-smokers can be effectively treated by molecularly targeted drugs that inhibit each oncoprotein. Moreover, from a pathological aspect, lung adenocarcinoma in never-smokers is characterized by terminal respiratory unit-type adenocarcinoma and a particular gene expression profile. Finally, epidemiological analyses have identified many candidate causes of lung cancer in never-smokers (genetic, environmental, and hormonal factors). The elucidation of the particular features of lung cancer unrelated to smoking and the development of new therapeutic modalities may reduce the mortality from lung cancers in the future.Keywords
This publication has 96 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Genetic variants and risk of lung cancer in never smokers: a genome-wide association studyThe Lancet Oncology, 2010
- Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancersOncogene, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002